All In Biotech

BLA 761197 · Genentech INC

Susvimo

Ranibizumab · Injection · Vascular Endothelial Growth Factor Inhibitor

Priority review

Last checked: Nov 20, 2026Latest source record: Sep 5, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Oct 22, 2021

Approved uses

3

Original approval plus efficacy supplements

Registered trials

538

153 Phase 3, 12 recruiting

FAERS reports

5,319

5,059 serious, 751 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ENDOPHTHALMITIS The SUSVIMO implant has been associated with an up to 3-fold higher rate of endophthalmitis than monthly intravitreal injections of ranibizumab. Many of these events were associated with conjunctival retractions or erosions. Appropriate conjunctiva management and early detection with surgical repair of conjunctival retractions or erosions may reduce the risk of endophthalmitis. [see Contraindications (4.1) , Warnings and Precautions (5.1) ] . WARNING: ENDOPHTHALMITIS See full prescribing information for complete boxed warning. The SUSVIMO implant has been associated with an up to 3-fold higher rate of endophthalmitis than monthly intravitreal injections of ranibizumab.

What it is approved for

From the label in effect Nov 21, 2025.

SUSVIMO (ranibizumab injection) is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (wet) Age-related Macular Degeneration (AMD) who have previously responded to at least two intravitreal injections of a VEGF inhibitor ( 1.1 ). Diabetic Macular Edema (DME) who have previously responded to at least two intravitreal injections of a VEGF inhibitor ( 1.2 ). Diabetic Retinopathy (DR) who have previously responded to at least two intravitreal injections of a VEGF inhibitor ( 1.3 ). 1.1 Neovascular (wet) Age-related Macular Degeneration (AMD) SUSVIMO (ranibizumab injection) is indicated for the treatment of patients with Neovascular (wet) Age-related Macular Degeneration (AMD) who have previously responded to at least two intravitreal injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor medication. 1.2 Diabetic Macular Edema (DME) SUSVIMO (ranibizumab injection) is indicated for the treatment of patients with Diabetic Macular Edema (DME) who have previously responded to at least two intravitreal injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor medication. 1.3 Diabetic Retinopathy (DR) SUSVIMO (ranibizumab injection) is indicated for the treatment of patients with Diabetic Retinopathy (DR) who have previously responded to at least two intravitreal injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor medication.

Mechanism: Ranibizumab binds to the receptor binding site of multiple biologically active forms of VEGF-A, including VEGF 110 . VEGF-A has been shown to cause neovascularization and leakage in models of ocular angiogenesis and vascular occlusion and is thought to contribute to pathophysiology of neovascular AMD. The binding of ranibizumab to VEGF-A prevents the interaction of VEGF-A with its receptors (VEGFR1 and VEGFR2) on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 21, 2025 Supplement 7 · Efficacy LetterLabel
  • Feb 3, 2025 Supplement 6 · Efficacy LabelLetter
  • Oct 22, 2021 Original approval · Type 2 - New Active Ingredient · priority review LetterLabelReview
1 products under this application
  • SUSVIMO · RANIBIZUMAB 100MG/ML · SOLUTION, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ranibizumab" as an intervention, any sponsor and status, largest first.

All 538 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • visual acuity reduced545
  • death380
  • off label use295
  • retinal haemorrhage270
  • cerebrovascular accident265
  • vitreous haemorrhage214
  • drug ineffective209
  • endophthalmitis207
  • myocardial infarction181
  • visual impairment172
  • cataract164
  • retinal pigment epithelial tear149

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20063
200753
200867
2009142
2010241
2011240
2012565
2013996
2014442
2015334
2016234
2017193
2018208
2019208
2020129
2021162
2022253
2023277
2024210
2025219
2026143

Recalls

1 FDA enforcement reports for this application.

  • Oct 18, 2022 · Class III · Terminated

    Defective Delivery System: Commercial implants do not meet the filed specification for the intended use, a few patients have experienced an issue with the implants that renders it non-functioning.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Susvimo* (Ranibizumab*) · HCPCS J2779

2024 spending

$2.2M

Beneficiaries

195

294 claims

Per beneficiary

$11,516

2024 ASP limit $80.18 per unit

View as table
YearSpending
2020$0
2021$0
2022$825,096
2023$1,669,238
2024$2,245,604

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,042 on PubMed

Sponsor: Roche (Genentech)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.